Skip to main content

Argenx SE

ARGX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001697862

No open-market purchases or sales by Argenx SE insiders were filed in the last 90 days; 510 institutions reported holding it in 13F filings for Q2 2026, worth $26.1B in total; no superinvestor holds it.

Superinvestors holding ARGX, Q2 2026

See all superinvestors

No superinvestor reported holding ARGX in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of ARGX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2024

    0 superinvestors holding at quarter end

    Sold out
    Soros Fund Management
  2. Q1 2024

    1 superinvestor holding at quarter end

    New
    Soros Fund Management
  3. Q4 2023

    0 superinvestors holding at quarter end

    Sold out
    HHLR Advisors (Hillhouse)
  4. Q3 2023

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−10.2%)
  5. Q2 2023

    1 superinvestor holding at quarter end

    New
    HHLR Advisors (Hillhouse)
  6. Q2 2022

    0 superinvestors holding at quarter end

    Sold out
    HHLR Advisors (Hillhouse)
  7. Q3 2021

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−66.4%)
  8. Q2 2021

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−4.9%)
    Sold out
    Lone Pine Capital